Page 137 - 《中国药房》2024年10期

参考文献 lar carcinoma[J]. Oncol Lett，2015，10（2）：778-784.
[ 1 ] MOU L S，TIAN X H，ZHOU B，et al. Improving out‐ [13] YANG Q Z，GAO L H，HUANG X L，et al. Sorafenib pre‐
comes of tyrosine kinase inhibitors in hepatocellular carci‐ vents the proliferation and induces the apoptosis of liver
noma：new data and ongoing trials[J]. Front Oncol，2021， cancer cells by regulating autophagy and hypoxia-
11：752725. inducible factor-1[J]. Exp Ther Med，2021，22（3）：980.
[ 2 ] HUANG W J，JENG Y M，LAI H S，et al. Expression of [14] STOCKWELL B R. Ferroptosis turns 10：emerging
hypoxic marker carbonic anhydrase Ⅸ predicts poor prog‐ mechanisms，physiological functions，and therapeutic
nosis in resectable hepatocellular carcinoma[J]. PLoS applications[J]. Cell，2022，185（14）：2401-2421.
One，2015，10（3）：e0119181. [15] YANG Z，SU W，WEI X Y，et al. HIF-1α drives resis‐
[ 3 ] JAYSON G C，KERBEL R，ELLIS L M，et al. Antiangio‐ tance to ferroptosis in solid tumors by promoting lactate
genic therapy in oncology：current status and future direc‐ production and activating SLC1A1[J]. Cell Rep，2023，42
tions[J]. Lancet，2016，388（10043）：518-529. （8）：112945.
[ 4 ] JU C，COLGAN S P，ELTZSCHIG H K. Hypoxia- [16] LI Y，YANG W J，ZHENG Y Y，et al. Targeting fatty acid
inducible factors as molecular targets for liver diseases[J]. synthase modulates sensitivity of hepatocellular carci‐
J Mol Med，2016，94（6）：613-627. noma to sorafenib via ferroptosis[J]. J Exp Clin Cancer
[ 5 ] LONG Q，ZOU X J，SONG Y，et al. PFKFB3/HIF-1α Res，2023，42（1）：6.
feedback loop modulates sorafenib resistance in hepatocel‐ [17] GAO Y，TONG M，WONG T L，et al. Long noncoding
lular carcinoma cells[J]. Biochem Biophys Res Commun， RNA URB1-antisense RNA 1 （AS1） suppresses
2019，513（3）：642-650. sorafenib-induced ferroptosis in hepatocellular carcinoma
[ 6 ] GAO R Z，BUECHEL D，KALATHUR R K R，et al. by driving ferritin phase separation[J]. ACS Nano，2023，
USP29-mediated HIF1α stabilization is associated with 17（22）：22240-22258.
sorafenib resistance of hepatocellular carcinoma cells by [18] QIU Y X，SHAN W Q，YANG Y，et al. Reversal of
upregulating glycolysis[J]. Oncogenesis，2021，10（7）：52. sorafenib resistance in hepatocellular carcinoma：epige‐
[ 7 ] LI S N，LI J J，DAI W Q，et al. Genistein suppresses aero‐ netically regulated disruption of 14-3-3η/hypoxia-
bic glycolysis and induces hepatocellular carcinoma cell inducible factor-1α[J]. Cell Death Discov，2019，5：120.
death[J]. Br J Cancer，2017，117（10）：1518-1528. [19] ZHU M，YIN F，FAN X，et al. Decreased TIP30 promotes
[ 8 ] WU F Q，FANG T，YU L X，et al. ADRB2 signaling pro‐ snail-mediated epithelial-mesenchymal transition and
motes HCC progression and sorafenib resistance by inhibi- tumor-initiating properties in hepatocellular carcinoma[J].
ting autophagic degradation of HIF1α[J]. J Hepatol，2016， Oncogene，2015，34（11）：1420-1431.
65（2）：314-324. [20] YOU A B，CAO M Q，GUO Z G，et al. Metformin sensi‐
[ 9 ] BORT A，SÁNCHEZ B G，MATEOS-GÓMEZ P A，et al. tizes sorafenib to inhibit postoperative recurrence and me‐
Targeting AMP-activated kinase impacts hepatocellular tastasis of hepatocellular carcinoma in orthotopic mouse
cancer stem cells induced by long-term treatment with models[J]. J Hematol Oncol，2016，9：20.
sorafenib[J]. Mol Oncol，2019，13（5）：1311-1331. [21] MÉNDEZ-BLANCO C，FONDEVILA F，FERNÁNDEZ-
[10] DONG X F，LIU T Q，ZHI X T，et al. COX-2/PGE2 axis PALANCA P，et al. Stabilization of hypoxia-inducible
regulates HIF2α activity to promote hepatocellular carci‐ factors and BNIP3 promoter methylation contribute to
noma hypoxic response and reduce the sensitivity of acquired sorafenib resistance in human hepatocarcinoma
sorafenib treatment[J]. Clin Cancer Res，2018，24（13）： cells[J]. Cancers，2019，11（12）：1984.
3204-3216. [22] SONG Z，LIU T F，CHEN J，et al. HIF-1α-induced RIT1
[11] HU W W，ZHENG S F，GUO H X，et al. PLAGL2-EGFR- promotes liver cancer growth and metastasis and its defi‐
HIF-1/2α signaling loop promotes HCC progression and ciency increases sensitivity to sorafenib[J]. Cancer Lett，
erlotinib insensitivity[J]. Hepatology，2021，73（2）： 2019，460：96-107.
674-691. [23] FERNÁNDEZ-PALANCA P，PAYO-SERAFÍN T，SAN-
[12] LIU F，DONG X F，LV H，et al. Targeting hypoxia- MIGUEL B，et al. Hepatocellular carcinoma cells lose len‐
inducible factor-2α enhances sorafenib antitumor activity vatinib efficacy in vitro through autophagy and hypoxia
via β-catenin/C-Myc-dependent pathways in hepatocellu‐ response-derived neuropilin-1 degradation[J]. Acta Phar‐

中国药房 2024年第35卷第10期 China Pharmacy 2024 Vol. 35 No. 10 · 1283 ·